INTRODUCTION AND OBJECTIVES:
A thermo-sensitive antiadhesive with a property of sol-gel transition was manufactured by a physical mixture of Poloxamer, Chitosan and Gelatin. Poloxamerbased thermo-sensitive sol-gel has been developed to reduce the incidence of postoperative adhesion formation. The purpose of this study was to evaluate the effect of poloxamer-based thermo-sensitive sol-gel instillation after transurethral resection of the prostate (TURP) on preventing urethral stricture.
METHODS: A total of 198 patients underwent TURP for benign prostatic hyperplasia.
Recruited patients were randomly divided into two groups: Groups A and B. Patients in group A (100 patients, experimental group) received poloxamer-based thermo-sensitive sol-gel instillation, and patients in the group B (98 patients, control group) received lubricant instillation after TURP. Each patient was evaluated at 4 weeks (V1), 12 weeks (V2), and 24 weeks (V3) after the surgery. The effectiveness of poloxamer-based thermo-sensitive sol-gel instillation was evaluated based on the International Prostate Symptom Score (IPSS)/Quality of Life (QoL), Overactive bladder questionnaire (OAB-q), peak urine ï:‚ow rate (Qmax), voided volume, postvoid residual volume (PVR) and cystoscopy.
RESULTS: Among 198 initial participants, 80 patients in group A and 83 patients in group B had completed theexperiment. There were no significant difference in IPSS/QoL, and OAB-q. However, Qmax (mL/ sec) showed significant difference between group A and group B (18.92AE9.98 vs. 15.58AE9.24, p[0.028) in 24 weeks after surgery. Also, result of PVR (mL) 24 weeks after surgery had significant difference between group A and group B (17.81AE28.33 vs. 30.12AE51.92, p[0.061) . By Cystoscopy, urethral stricture after TURP was seen in 2 of 80 subjects in group A and 10 of 83 subjects in group B (p[0.023).
CONCLUSIONS: Poloxamer-based thermo-sensitive sol-gel instillation after TURP decreased the incidence of urethral stricture.
Source of Funding: This study was sponsored by Daewoong Pharmaceutical Co LTD, Seoul,Korea.
MP01-07 PROSTACARE: WATER ELECTROLYSIS SYSTEM FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA
Yong Wei Lim*, Ho Yee Tiong, Wei Jin Chua, Soon Phang Allen Sim, Sun Sien Henry Ho, Singapore, Singapore INTRODUCTION AND OBJECTIVES: Established treatment of benign prostate hyperplasia (BPH) with medical or surgical therapy provides symptom relief but have associated serious side effects. New technology offers treatment options which aim to minimise these side effects. The ProstaCare water electrolysis system was developed to treat BPH by creating necrosis in the lateral lobes of the prostate around the urethra. Water electrolysis is achieved by passing direct current between a pair of electrodes in tissue. This creates hydroxyl ions at the cathode and hydrogen ions at the anode. The resulting acidic and alkaline regions cause cellular necrosis. The ions created are proportional to the charge passing through the electrodes and an ion concentration gradient ensures as they diffuse through the tissue. The controlled shape and size of the concentration gradient allow for the predictable creation of necrotic treatment zones.
We report our multi-centre clinical experience with ProstaCare water electrolysis treatment of prostate for BPH and the outcomes with 12 months follow-up.
METHODS: A total of n[49 patients with moderate to severe lower urinary tract symptoms (LUTS) were recruited in a single arm study. The ProstaCare treatment catheter device was inserted per urethra using lignocaine gel as local anaesthesia. The pre and post procedure assessments included International Prostate Symptom Score (IPSS), Quality of Life (QOL) score, and peak urinary flow rate. The duration the patient had a catheter was also recorded. RESULTS: Our patients were aged (years) median 66, range (51-86) with prostate volume (ml) median 39, range (27-54.9). They reported significant improvement in IPSS, QOL and peak urinary flow rate through 12 months after water electrolysis therapy. The mean improvement in IPSS of -9.6 was sustained from the 3 months through to the 12 months follow up (p[0.004). The mean improvement in QOL of -2.1 at 3 months reduced to -1.5 at the 12 months follow up (p[<0.001). The mean peak urinary flow rate improvement of Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e3
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